Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
fda
3
×
life sciences
national blog main
3
×
boston blog main
boston top stories
deals
new york blog main
san diego blog main
san diego top stories
the medicines company
achaogen
adams street partners
alirocumab
alnylam pharmaceuticals
amgen
antibiotics
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
biotech ipos
boston
drug resistance
drugs
dyne therapeutics
evolocumab
hatteras venture partners
inclisiran
investing
lyzz capital
macrolide pharmaceuticals
melinta therapeutics
meropenem
metacrine
michael dudley
myotonic dystrophy type 1
national top stories
new enterprise associates
new york
new york top stories
What
company
3
×
drug
3
×
medicines
brings
therapeutics
acquire
agreed
bacteria
billion
biopharma
business
cash
cholesterol
compound
deal
developing
disease
disorders
dyne
dyne’s
exited
fda
fighting
genetic
infections
infectious
ipo
launches
medco
melinta
million
muscle
muscular
new
novartis
poised
preclinical
products
qpex
raised
Language
unset
Current search:
fda
×
drug
×
" national blog main "
×
company
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections